These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18796377)

  • 1. Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
    Lázaro A; Casinello J; Amorós A; Heredia M; López-Alfonso A
    Clin Transl Oncol; 2008 Sep; 10(9):587-90. PubMed ID: 18796377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
    Ishida T; Kiba T; Takeda M; Matsuyama K; Teramukai S; Ishiwata R; Masuda N; Takatsuka Y; Noguchi S; Ishioka C; Fukushima M; Ohuchi N
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):361-9. PubMed ID: 19082596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
    Morohashi S; Odagiri H; Morohashi H; Kimura Y; Sasaki M
    Breast Cancer; 2007; 14(3):297-301. PubMed ID: 17690508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
    Bianchi GV; Duca M; Sica L; Mariani G
    Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
    Nakamura Y; Aono T; Nomura M; Iwase K; Tanaka Y
    Gan To Kagaku Ryoho; 2010 Nov; 37(11):2165-8. PubMed ID: 21084819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
    Yoshidome K; Imabun S; Nakahara M; Hiraoka K; Yamagami Y; Tsujimoto M; Nakao K
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1453-6. PubMed ID: 17033236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
    Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
    Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
    Yabe N; Murai S; Shimizu H; Kitasato K; Yoshikawa T; Oto I; Nakadai J; Jinno H; Kitagawa Y
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2396-8. PubMed ID: 24394124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
    Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
    Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    Shigematsu H; Nakamura Y; Tanaka K; Shiotani S; Koga C; Kawaguchi H; Nishimura S; Taguchi K; Nishiyama K; Ohno S
    Int J Clin Oncol; 2010 Dec; 15(6):615-20. PubMed ID: 20473628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
    Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
    Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
    von Minckwitz G; Rezai M; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Blohmer JU; Costa SD; Jackisch C; Paepke S; Schneeweiss A; Kümmel S; Denkert C; Mehta K; Loibl S; Untch M
    Ann Oncol; 2014 Jan; 25(1):81-9. PubMed ID: 24273046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
    Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
    Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
    von Minckwitz G; du Bois A; Schmidt M; Maass N; Cufer T; de Jongh FE; Maartense E; Zielinski C; Kaufmann M; Bauer W; Baumann KH; Clemens MR; Duerr R; Uleer C; Andersson M; Stein RC; Nekljudova V; Loibl S
    J Clin Oncol; 2009 Apr; 27(12):1999-2006. PubMed ID: 19289619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
    Shigekawa T; Takeuchi H; Misumi M; Matsuura K; Sano H; Fujiuchi N; Okubo K; Osaki A; Aogi K; Saeki T
    Breast Cancer; 2009; 16(1):88-92. PubMed ID: 18478315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
    Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
    Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
    Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
    Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.